Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10711MR)

This product GTTS-WQ10711MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ALB&IL17A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized; Vicugna pacos (alpaca)
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3605
UniProt ID P02768; Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10711MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10356MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ7517MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ4373MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ6873MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ11424MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ10295MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ1402MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ169MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW